Not Yet RecruitingNot Applicable

Utilizing Carbon Dioxide for Assessing Coronary Blood Flow in Subjects With Coronary Artery Disease

United States30 participantsStarted 2026-01-10

Plain-language summary

This is a prospective pilot study to evaluate the safety, tolerability and technical feasibility of utilizing carbon dioxide for assessing coronary blood flow in subjects with coronary artery disease.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adults \> 18 years of age
✓. Clinically stable individuals with suspected or known coronary artery disease (CAD)
✓. The SPECT/PET study indicates at least a mild to moderate myocardial ischemia (\>5-9%) or fractional-flow-reserve (FFR) of \<0.75.

Exclusion criteria

✕. Prior myocardial infarction by clinical history (subjects with prior coronary revascularization without myocardial infarction will not be excluded)
✕. Hypotension (systolic blood pressure \< 100 mmHg)
✕. Significant non-coronary cardiac disease (e.g., valvular abnormality, or cardiomyopathy, etc.)
✕. Inability to schedule the research study within 30 days of the SPECT/PET study and prior to any coronary revascularization procedure
✕. Inability to voluntarily increase their breathing rate if prompted to do so
✕. Persons with mechanically, magnetically, or electrically activated implants (such as cardiac pacemakers, neurostimulators, and infusion pumps), with ferromagnetic implants or foreign bodies (such as intracranial, aneurysm clips, shrapnel, and intraocular metal chips)
✕. Persons who are pregnant, nursing, or implanted with intrauterine devices (IUD's)
✕. Persons with a history of significant heart, lung, kidney, or liver disease

What they're measuring

Ratio of Maximum Signal Intensity (MSI) by BOLD MRI

Timeframe: 3 hours

Ratio of Maximum Signal Intensity (MSI) by FFP MRI

Timeframe: 3 hours

Trial details

NCT IDNCT06253884

SponsorIndiana University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-06-15

Contact for this trial

Chandana Saha, PhD

317 274 0975 csaha@iu.edu

View on ClinicalTrials.gov More Coronary Artery Disease trials